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Abstract
An essential component of therapeutic drug/biomarker monitoring (TDM) is to combine
patient data with prior knowledge for model-based predictions of therapy outcomes. Cur-
rent Bayesian forecasting tools typically rely only on the most probable model parameters
(maximum a-posteriori (MAP) estimate). This MAP-based approach, however, does neither
necessarily predict the most probable outcome nor does it quantify the risks of treatment
inefficacy or toxicity. Bayesian data assimilation (DA) methods overcome these limitations
by providing a comprehensive uncertainty quantification. We compare DA methods with
MAP-based approaches and show how probabilistic statements about key markers related to
chemotherapy-induced neutropenia can be leveraged for more informative decision support
in individualised chemotherapy. Sequential Bayesian DA proved to be most computational
efficient for handling interoccasion variability and integrating TDM data. For new digital
monitoring devices enabling more frequent data collection, these features will be of critical
importance to improve patient care decisions in various therapeutic areas.
INTRODUCTION
In the presence of a narrow therapeutic window and large inter-patient variability, therapeutic
drug/ biomarker monitoring (TDM) is indicated for safe and efficacious therapies. With the help
of Bayesian forecasting tools, patient-specific data are combined with prior knowledge from previ-
ous clinical studies and a drug-specific model to enable model-informed precision dosing (MIPD)
[1]. Typically, only the most probable individual parameter values, i.e., the maximum a-posteriori
(MAP) estimates, are used to predict the individual therapy outcome without quantifying associ-
ated uncertainties [2]. Thus, relevant risks associated with a dosing regimen selection, e.g. treat-
ment inefficacy or unacceptable toxicity, are not determined hindering a well-founded therapeutic
decision-making.
In this article, we thoroughly compare in a TDM context Bayesian data assimilation (DA) methods
that allow for a comprehensive uncertainty quantification by estimating the full posterior distribu-
tion (termed full Bayesian approach) in contrast to MAP estimation and a normal approximation
(NAP) to the posterior at the MAP estimate. The full Bayesian approaches comprise not only
methods that process patient data collected over time in a batch (i.e., all at once), like Markov
chain Monte Carlo (MCMC) and sampling importance resampling (SIR), but also particle filters
(PF) that allow for efficient sequential data processing. PF are well established in areas of applica-
tion in which real-time predictions based on online/monitoring data are required, as in navigation,
meteorology and tracking [3, 4, 5].
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In the context of chemotherapy-induced neutropenia—the most frequent dose-limiting side effect
for cytotoxic anticancer drugs with substantial decrease of neutrophil granulocytes and thus po-
tentially life-threatening fever and infections [6]—we demonstrate the clear benefits of uncertainty
quantification compared to purely MAP-based predictions (as, e.g., in [7]) using the gold-standard
model for neutropenia [8]. Further, we compare the full Bayesian approaches regarding quality of
uncertainty quantification and computational runtime for multiple cycle chemotherapy [9]. While
MCMC, SIR and PF all provide a reliable uncertainty quantification, the efficient data processing
of the sequential approach will be clearly beneficial in a continuous monitoring context, where
digital health care devices (e.g. wearables) allow patients to measure and report individual marker
concentrations online.
METHODS
First, the statistical framework of MIPD in TDM is introduced, which is used throughout the
different methods described below. Then, the considered clinical application scenarios are described
along with the prior knowledge from literature.
Statistical framework
TDM in the context of MIPD builds on prior knowledge in form of a structural, observational,
covariate and statistical model. In the sequel, TDM data are considered for a single individual and
therefore there is no running index for individuals. The structural and observational models are
given as
dx
dt
(t) = f(x(t); θ, u), x(t0) = x0(θ) (1)
h(t) = h(x(t), θ) (2)
with state vector x = x(t) (incl. drug/biomarker concentrations), individual parameter values θ
(e.g., volumes, clearances) and rates of change f(x; θ, u) of all state variables for a given input u
(e.g., dose). Since typically only a part of the state variables is observed, the function h maps x to
the observed quantities h(x, θ), e.g., plasma drug or neutrophil concentration, including potential
state-space transformations (e.g., log-transformed output). The initial conditions x0 are defined
by the pre-treatment levels (e.g., baseline values). The covariate and statistical model link the
patient-specific covariates ‘cov’ and observations (tj , yj)j=1,...,n to the model predictions hj(θ) =
h(x(tj), θ), accounting for measurement errors and possibly model misspecification,
Yj|Θ=θ ∼ p
( · |θ;hj(θ),Σ) , j = 1, . . . , n (independent) (3)
Θ ∼ pΘ
( · ; θTV(cov),Ω) , (4)
where θTV(cov) denotes the typical hyper-parameter values (TV) that might depend on covariates.
The dot (‘·’) in a probability distribution serves as placeholder for its argument. Often, Yj|Θ=θ =
hj(θ) + j with j ∼iid N (0,Σ). Prior knowledge about the parameters is provided by population
analyses of clinical studies, in which nonlinear mixed effects (NLME) approaches are used to
estimate the functional relationship cov 7→ θTV(cov), and the parameters Σ and Ω.
The challenge in MIPD is to infer information on the individual parameter values θ of a patient
based on his/her covariate values and measurements. Here, a Bayesian approach is highly benefi-
cial: the unexplained inter-individual variability in the population model (Eq. 4) defines the prior
uncertainty about the individual parameter values. In this context, the hyperparameters, i.e., all
parameters after the semicolon in Eq. 4, are assumed to be known (fixed). As a consequence, we
drop them as well as the subscripts in the notation in the sequel. As a result, the likelihood at
the individual level reads p(·|θ) = p(·|θ;hj(θ),Σ) and the prior p(·) = pΘ( · ; θTV(cov),Ω). Then,
assimilating measurements y1:n = (y1, . . . , yn)
T into the model based on Bayes’ formula
p(θ|y1:n) = p(y1:n|θ) · p(θ)
p(y1:n)
(5)
allows to learn about individual parameter values from the data. The remaining uncertainty of
parameter values is encoded in the posterior p(·|y1:n). Note that p(y1:n|θ) = p(y1|θ) · . . . · p(yn|θ)
2
due to independence in Eq. 3. The denominator p(y1:n) in Eq. 5 serves as a normalisation factor,
denoting the probability of the data. In contrast to MAP estimation, which summarises the
posterior by its mode, Bayesian DA approaches rely on sample approximations of the posterior
p(θ|y1:n) ≈
S∑
s=1
w(s)n δθ(s)n
(θ) (6)
based on a sample
Sn :=
{(
θ(s)n , w
(s)
n
)
, s = 1, . . . , S
}
,
with sample parameters θ
(s)
n of the posterior [10, section 2.5], weights w
(s)
n , which sum to one, i.e.∑S
s=1 w
(s)
n =1 and point masses δθ(s)n
at θ
(s)
n . If w
(s)
n = 1/S for all s, the sample is called unweighted.
Based on the posterior sample, we may also approximate quantities of interest in the observable
space by solving Eq. 1+2 for all elements in Sn. This serves also as the basis for credible intervals;
applying subsequently the residual error model Eq. 3 is the basis for prediction intervals.
Since direct sampling from the posterior is in general not possible, alternative approaches (described
below) need to be employed to generate a sample of the posterior. For a detailed description, see
Section S 3 - S 7.
Maximum a-posteriori (MAP) estimation
MAP estimation approximates the mode of the posterior distribution, i.e., the most probable
parameter values given patient-specific measurements y1:n:
θˆMAPn = arg max
θ
p(θ|y1:n). (7)
The MAP estimate θˆMAPn is a one-point summary of the posterior distribution, without quantifi-
cation of the associated uncertainty.
Normal approximation (NAP)
To overcome the one-point summary limitation of the MAP estimate, the posterior p(·|y1:n) may
be approximated locally by a normal distribution located at the MAP estimate [11, section 4.1]
p(·|y1:n) ≈ N
(
θˆMAPn , I−1
(
θˆMAPn
))
, (8)
where I denotes the total observed Fisher information matrix [12, section 2.5]
I(θ) := Ipost(θ) = − d2
dθ2
log p(θ|y1:n)
of the posterior. The uncertainty in the parameters is then propagated to the observables by first
sampling from the normal distribution in Eq. 8 and then solving the structural model for each
sample [13]. Alternatively to this sampling-based approach, the Delta method [14, section 5.5]
could be used, see also Section S 4.
Sampling Importance Resampling (SIR)
The SIR algorithm is a full Bayesian approach. It generates an unweighted sample Sn from the pos-
terior p(θ|y1:n) based on a sample from a so-called importance distribution G, from which samples
can easily be generated [11, section 10.4]. SIR proceeds in three steps. S-Step: iid. sampling from
the importance distribution G resulting in a sample S˜n. We considered the prior as importance
distribution, assuming that the patient under consideration is sufficiently well represented by the
clinical patient populations given by the prior. I-Step: Each sample point θ˜
(s)
n ∈ S˜n is assigned
an importance weight w˜
(s)
n = p
(
y1:n|θ˜(s)n
)
given by the likelihood (in case G is the prior). R-Step:
After normalisation of the weights w
(s)
n = w˜
(s)
n /
∑
s w˜
(s)
n , a resampling is performed: S unweighted
samples θ
(s)
n are drawn from θ˜
(s)
n according to weights w
(s)
n .
3
Note that once a new data point yn+1 becomes available, the SIR algorithm does not simply update
the present sample points θ
(s)
n in Sn, but re-performs all three steps based on the updated posterior
p
( · |y1:n+1) to determine Sn+1.
Markov chain Monte Carlo (MCMC)
A popular alternative to SIR in Bayesian inference are MCMC methods with a wide range of
different algorithms, see e.g. [15]. MCMC generates an unweighted sample Sn from the posterior
by means of a Markov chain [11, section 11]. MCMC comprises two steps to generate sample
points θ
(s)
n : a proposal step (generating a potential new sample point θ∗) and an acceptance step
(accepting or rejecting θ∗ as a new sample point). The challenge in MCMC is to design application-
specific proposal distributions.
In TDM, MCMC was previously considered with the prior as fixed proposal distribution (inde-
pendence sampler) for sparse patient monitoring data [16]. We observed, however, large rejection
rates with increasing number n of data points, since the posterior becomes narrower, see Sec-
tion S 8. To counteract large rejection rates, we used an adaptive Metropolis-Hastings sampler
with log-normally distributed proposal distribution (see Section S 6 for details).
Particle filtering (PF)
In contrast to SIR and MCMC, which process data in a batch, PF constitutes a sequential ap-
proach to DA, see [17, 3, 18] for a detailed introduction. Given a weighted sample Sn of the
posterior p(·|y1:n) and a new data point yn+1, PF generates a weighted sample Sn+1 of the poste-
rior p(·|y1:n+1) by updating Sn using a sequential version of Bayes formula
p(θ|y1:n+1) ∝ p(yn+1|θ) · p(θ|y1:n). (9)
For n = 0, the distribution p(θ|y1:0) is identical to the prior p(θ) [10, section 3]. Note that
p(yn+1|θ) = p(yn+1|y1:n, θ) due to independence in Eq. 3. Analogously to the I-step in SIR, the
weights w
(s)
n are updated proportional to the (local) likelihood: w
(s)
n+1 ∝ p(yn+1|θ) ·w(s)n involving,
however, only the new data point yn+1. As in SIR and MCMC, evaluation of the likelihood involves
solving the structural model (1). Since the structural model is deterministic, one may either solve
Eq. 1 with initial condition x0(θ) for the total timespan [t0, tn+1], or with initial condition xn(θ)
for the incremental timespan [tn, tn+1]. The latter approach requires to store for each sample point
(θ
(s)
n , w
(s)
n ) also the corresponding state x
(s)
n at time tn, since typically the structural model cannot
be solved analytically. The incremental approach makes use of the Markov property that the future
state is independent of the past when the present state is known.
The resulting triple
(
θ
(s)
n , w
(s)
n , x
(s)
n
)
is called a particle. In our setting, the ensemble of particles
can be interpreted as the state of a population of virtual individuals at time tn, whose “diversity”
represents the uncertainty about the state/parameters of the patient at time tn, given the individual
measurements y1:n. The posterior p(·|y1:n) obtained by n sequential update steps in Eq. 9 is
mathematically identical to the posterior obtained in Eq. 5 by assimilating all data y1:n in a batch
[19, section 3.3.3]. However, the sequential update is much more efficient as it involves a reduced
integration time span.
In contrast to SIR, PF does not perform resampling by default. Only if too many samples carry an
almost negligible weight and the total weight is limited to only a few samples (weight degeneracy),
a resampling is performed. We used a criterion based on the effective sample size
Seff(tn) :=
1∑S
s=1
(
w
(s)
n
)2
to decide whether to resample. Starting initially with uniform weights w
(s)
0 = 1/S with Seff(t0) = S,
resampling was carried out once Seff < S/2 (effective ensemble size half of the initial ensemble size).
If resampling is performed, it is followed by a so-called rejuvenation step [3] to prevent sample
impoverishment by fixation to limited parameter values:
θ(s)n = θ˜
(s)
n + ξ
(s)
n , with ξ
(s)
n ∼iid N (0, τ · |θ˜(s)n |)
4
with rejuvenation parameter τ , where θ˜
(s)
n denotes the resampled parameters. These two steps,
resampling and rejuvenation, ensure that the weighted sample Sn adequately represents areas of
posterior probability.
Biomarker data during chemotherapy for single/multiple cycle simulation
studies
Two simulation studies (see below) were performed to analyse the approaches regarding their
suitability to support MIPD.
For the single cycle study with docetaxel (100 mg/m
2
, 1 h infusion), we used the NLME model in
[20]. It is based on the well-known pharmacodynamic (PD) model in [8] (Figure S 6) and describes
the effect of a single dose of the anticancer drug docetaxel based on monitoring neutrophil counts.
Important model paramters are the drug effect parameter ‘Slope’ and the pre-treatment baseline
neutrophil concentration ‘Circ0’. For inference, neutrophil concentrations were considered on a
log-scale at time points t = 0, 3, . . . , 21 days post-dose. See Section S 8 for full details. This
simulation study aims to demonstrate the limitations of MAP estimation for a model frequently
used in MIPD for TDM (see, e.g. [7, 21]). Since recursive data processing and decision-support gain
in relevance for long-term monitoring, we performed a simulation study for multiple cycle therapy
with paclitaxel using the NLME model in [9]. It describes the effect of the anticancer drug paclitaxel
(200 mg/m
2
, 3 h infusion) over 6 cycles of 3 weeks each, corresponding to treatment arm A of the
CEPAC/TDM study [22]. In [9], an aggravation of neutropenia over subsequent treatment cycles
is accounted for by bone marrow exhaustion [9] (Figure S 6). The model includes interoccasion
variability (IOV) on pharmacokinetic (PK) parameters describing the variability between cycles
within one patient. Therefore, the parameter values comprise the interindividual parameters (θIIV)
and a parameter for each occasion (θIOV). As a consequence, the size of θ increases with every
occasion/cycle: θ = (θIIV, θ
1
IOV, . . . , θ
nc
IOV), where nc denotes the number of cycles, see Section S 9
for details. Neutrophil counts were assumed to be monitored every third day.
We were interested in a setting where data become available sequentially (one-by-one). To this end,
neutrophil count data were simulated for a virtual patient using Eq. 3-4 and the corresponding
model. Then the individual parameter values were inferred based on the simulated neutrophil
count data available up to a certain time point, using the same model. For the statistical analysis,
this procedure was repeated for N = 100 virtual patients (with covariate characteristics mirroring
the real study population underlying the NLME model).
Key characteristics for decision-support in cytotoxic chemotherapy
We investigated different characteristics T (·) of the neutropenia time-course related to risk and
recovery [7]. Depending on the nadir, i.e., minimal neutrophil concentration, different grades of
neutropenia are distinguished, see Figure 1. Neutropenia grade 4 is dose-limiting as this severe
reduction in neutrophils exposes patients to life-threatening infections. On the contrary, neutrope-
nia grade 0 is also undesired as it is associated with a worse overall treatment outcome [24]. The
time tnadir, at which the nadir is reached, is important for time management of intervention. We
considered the patient out of risk at time trec2, when neutropenia grade 2 is reached post nadir.
For the initiation of the next treatment cycle, the recovery time trec0 to grade 0 is important. In
addition, risk is also related to the duration tdur3 and tdur4 of an individual being in grade 3 and
4 neutropenia, respectively.
Workflow in Bayesian forecasting
In full Bayesian forecasting, uncertainty is quantified on the parameter level and subsequently
propagated to the observable level, possibly summarised for some key quantities of interest, see
Figure 2. Prior to observing patient-specific data, the parameter uncertainty is characterised by
the prior (cmp. Eq. 4). It allows to make a-priori predictions of the neutropenia time course and
its uncertainty in form of a (1− α)-confidence interval. Also, a-priori predictions for quantities of
interest can be derived, e.g. the neutropenia grade (Figure 2, left column). Once patient-specific
data are assimilated into the Bayesian model, the remaining uncertainty on the parameter values
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Figure 1: Key characteristics for decision-making in cytotoxic chemotherapy related to
risk (dark blue) and recovery (light blue) of neutropenia. Neutropenia grades are defined according
to the Common Terminology Criteria for Adverse Events (CTCAE) [23]. Note that the shades of
red are related to the increasing toxicity, however, grade 0 (white) over the whole cycle is associated
with ineffective treatment. As key statistics for decision support we consider the lowest neutrophil
concentration (cnadir), the time at which the nadir is reached (tnadir), the duration of neutropenia
grade 3 and grade 4 (tdur3 and tdur4,respectively), as well as the times until recovery to neutropenia
grade 2 and 0 ( trec2 and trec0, respectively).
is characterised by the posterior, allowing to update also the uncertainty in the observable space
(credible intervals CrI) and the quantities of interest (Figure 2, middle column).
Forward uncertainty propagation corresponds to transforming a probability distribution (prior or
posterior) under a (possibly nonlinear) mapping T (·), resulting in a transformed quantity ψ = T (θ).
For illustration, we assume the one-dimensional case with strictly increasing T and θ = T−1(ψ).
Then the posterior in terms of ψ is given by [25, section 1]
pΨ(ψ|y1:n) = pΘ(θ|y1:n) · dT
−1(ψ)
dψ
, (10)
which is approximated in sampling-based approaches (cf. Eq. 6) by
pˆΨ(ψ|y1:n) =
S∑
s=1
w(s)n δψ(s)(ψ) ,
with ψ(s) = T (θ(s)). This allows the computation of any desired summary statistic, e.g. posterior
expectation or quantiles. MAP estimation, in contrast, characterises the posterior by a single value
and allows only to make a single MAP-based prediction by mapping the MAP estimate θˆMAP to
the quantity of interest T (θˆMAP), lacking crucial information on its uncertainty (Figure 2, right
column). Importantly, for nonlinear T this does not result in the most probable outcome, due to
the Jacobian factor dθdψ =
dT−1(ψ)
dψ in Eq. 10 [26, 27]: The most probable outcome is defined as the
outcome with maximum posterior probability
ψˆMAPn = arg max
ψ
pΨ(ψ|y1:n) , (11)
which satisfies (assuming for illustration that T is strictly increasing)
0 =
d
dψ
pΨ(ψ|y1:n) Eq. 10= d
dψ
[
pΘ(T
−1(ψ)|y1:n) · dT
−1(ψ)
dψ
]
=
d
dθ
pΘ(T
−1(ψ)|y1:n) ·
(
dT−1(ψ)
dψ
)2
+ pΘ(T
−1(ψ)|y1:n) · d
2T−1(ψ)
dψ2
.
(12)
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Figure 2: Overview of the workflow in MIPD comparing full Bayesian inference to
MAP-based prediction. In full Bayesian inference uncertainties in the parameter values are
propagated to uncertainties in the observable space and quantities of interest. The posterior is
displayed for the parameters ’Slope’ (drug effect parameter) and ’Circ0’ (pre-treatment neutrophil
concentration). For the prior and Full Bayes approach samples (dots) from the distributions are
shown with contour levels. In the observable space the point estimates (solid lines) are displayed
with the central 90% confidence (CI) or credible intervals (CrI) (dashed lines and shaded area)
along with the TDM data (crosses). The a-priori/a-posteriori probabilities are calculated for the
neutropenia grades (grade 0-4).
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For the transformed MAP estimate ψ = T (θˆMAP), the first term in Eq. 12 is zero, since its first
factor vanishes by definition. The second term, however, is non-zero, since both its factors are
non-zero for nonlinear T . Therefore, the transformed MAP estimate does not satisfy the condition
for the mode of the transformed posterior probability and hence, T (θˆMAP) 6= ψˆMAP.
Method comparison
For all sampling-based methods (NAP, SIR, MCMC, PF) we used a sample of size S = 103. Since
the posterior is analytically intractable, an extensive sample of size S = 106 was used as reference
(generated by SIR and cross-checked with MCMC, see Figure S 7, since these approaches are exact
in the limit S → ∞). As a statistical measure for the quality of uncertainty quantification we
considered the Hellinger distance
H(Pˆ , P ref) :=
1√
2
√√√√ b∑
i=1
(√
p̂i −
√
prefi
)2
, (13)
which measures the difference between the discrete sampling-based a-posteriori probability dis-
tribution Pˆ = (p̂1, . . . , p̂b) and the reference solution P
ref = (pref1 , . . . , p
ref
b ) generated with SIR
S = 106 for b fixed bins.
RESULTS
First we show the limitations of MAP estimation for MIPD and how full Bayesian approaches can
overcome these limitations (using SIR with S = 106 for comparison). Next we compare different full
Bayesian approaches with reduced sample sizes regarding accuracy and computational efficiency.
Unfavourable properties of MAP-based predictions
The first example of decision support in individualised chemotherapy employs the most frequently
used model of neutropenia [8]. The MAP estimate θˆMAPn is derived from the parameter posterior
p(·|y1:n) given experimental data y1:n = (y1, . . . , yn)T , see Eq. 7. In the context of TDM, it is
used to predict the future time course x(t; θˆMAP) of the patient and thereon based observables.
In mathematical terms, θˆMAP is mapped to some quantity of interest T (θˆMAP), e.g., the nadir
concentration. As pharmacometric models are generally nonlinear, this does, however, not result in
the most probable outcome (see also paragraph preceding Eq. 12 in the Methods). This is due to the
fact that first determining the MAP estimate and then applying a nonlinear mapping is in general
different from first applying the mapping to the full parameter posterior and then determining its
MAP estimate: T
(
θ̂MAP
) 6= T̂ (θ)MAP, see Figure 3 for an illustration with T (θ) = cnadir(θ) and
Figure S 1 for more details.
Thus, MAP-based estimation lacks both, a measure of uncertainty and the feature to predict the
most probable observation/quantity of interest. In addition, relevant outcomes such as the risk of
grade 4 neutropenia can not be evaluated from the point estimate alone. MAP-based estimation,
therefore, provides a biased basis for clinical decision-making. In contrast, full Bayesian inference
provides access to the full posterior distribution of the parameters and correctly transforms un-
certainties forward to the observables and quantities of interest, allowing to compute any desired
summary statistic and relevant risks [19, section 5.2].
Uncertainty quantifications for more comprehensive, differentiated un-
derstanding and thus better informed decision-making
The first scenario served to demonstrate the limitations of MAP-based estimations for the gold-
standard model [8], however, the model does not account for the observed cumulative neutropenia
over multiple cycles. Therefore, we considered for dose adaptations a model accounting for bone
marrow exhaustion over multiple cycles [9], see paragraph about the multiple cycle study pacli-
taxel. We exemplarily considered the dose selection for the third treatment cycle based on prior
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Figure 3: MAP-based predicted nadir concentration is not the most (a-posteriori) prob-
able nadir concentration. We considered the single cycle study docetaxel with four observed
data points y1:4 and forecasted the nadir concentration based on the posterior p(θ|y1:4). The mode
is not preserved under nonlinear transformation (see text). Therefore, Cnadir(θˆ
MAP) with Cnadir(·)
denoting some observable T (·) does not equal the mode of the a-posteriori probability pT (Θ)(·|y1:n)
of the nadir concentration.
information and patient-specific measurements during the first two cycles. The patient-specific
data together with the full Bayesian model fit and prediction are shown in Figure 4 A. The cred-
ible intervals (dashed) and prediction intervals (dotted) show the uncertainty about the ‘state of
the patient’, without and with measurement errors, respectively.
For optimising the dose of the third cycle, different dosing scenarios were considered: the standard
dose and a −15%, −30% and +10% adapted dose. Figure 4 B shows the probability of the
predicted grades of the third cycle for each dose. To find an effective and safe dose, the risk of
being ineffective (neutropenia grade 0) should be minimised jointly with the risk of being unsafe
(neutropenia grade 4). For illustration in Figure 4 B, the dashed horizontal lines indicate a 10%
and 5% level of being ineffective and unsafe, respectively. The standard dose and the increased
dose have a risk of toxicity larger than 5% (lower horizontal line). A decrease in dose also leads to
an increased risk of an ineffective dose (upper horizontal line). The 15% reduced dose is with 96%
probability safe and efficacious (grade 1-3), with 3% probability ineffective (grade 0) and with 1%
probability unacceptably toxic (grade 4). If grade 3 is also to be avoided, the 30% reduction would
be preferable, as it is with 74% probability safe and efficacious (grade 1-2), with 15% probability
ineffective (grade 0) and with 11% probability toxic (grade 3-4). Thus, the choice of an optimal
dose might depend on how priority is given to the risk of inefficacy and toxicity. As both risks
are described by the tails of the posterior distribution, a point estimate is not able to adequately
capture them. The MAP-based predicted grades were: grade 2 (standard dose and +10% dose),
grade 1 (−15% dose); and grade 0 (−30% dose), which do not only make it difficult to distinguish
between some doses, but also do not reflect the true most probable grades.
Posterior-based predictions of important statistics related to the neutropenia time-course can help
to answer questions like “How probable is it that the patient will suffer from grade 4 neutropenia?”
or “How probable is it that the patient will recover in time for the next scheduled dose so that the
therapy can be continued as planned?”. To answer such questions, Figure 4 C shows important
predicted quantities of interest, illustrated for the standard dose in cycle 3. We inferred that the
risk of grade 4 neutropenia is 8%, and if the patient were to reach grade 4, it would be most
probable (68%) on day 12. The probability that the patient’s duration in grade 4 is a day or longer
is very small (< 7%). As the probability to not have been recovered until day 21 is negligible, the
9
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Figure 4: Uncertainty quantification by full Bayesian methods gives important infor-
mation for therapy dosing selection. The scenario described in multiple cycle study paclitaxel
is used and the results are shown for the reference solution with SIR using S = 106 samples. (A)
Forecasting the third cycle for different doses based on the patient’s covariates and measurements
of the first two cycles. (B) Full Bayesian inference allows for probabilistic statements of the differ-
ent grades. Colour coding of neutropenia grades shows trade-off between efficacy and toxicity. No
toxicity (grade 0) is associated with poorer treatment outcome (orange) but severe neutropenia
(grade 3 and 4) is also not desired (yellow and red). (C) A-posteriori probabilities of quantities
of interest for the third cycle based on the posterior at the end of second cycle (week 6) for the
standard dose. Statistics such as day of grade 4 were computed given that grade 4 is reached. Note
for all displayed forecasts the reference method (SIR with S = 106) was used.
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administration can remain scheduled on day 21 for cycle 4. Therefore, uncertainty quantification
improves the decision-making process by quantifying the a-posteriori probabilities of relevant risks
and quantities of interests. Repeating the above analysis for different doses therefore allows for an
improved distinction between dose adjustments.
Approximation accuracies comparable across different full Bayesian ap-
proaches
We next compared different established methods for uncertainty quantification with regard to
their approximation accuracy. To this end, posterior inference was investigated for a patient at
day 5 of the first cycle (Figure 5). Whereas the marginal posterior distribution for the parameter
‘Circ0’ (pre-treatment neutrophil concentration) is close to a normal distribution, the marginal
posterior for the drug effect parameter (‘Slope’) is closer to a log-normal distribution. Accordingly,
the normal approximation (NAP) is rather reasonable for ‘Circ0’, but is questionable for the
‘Slope’ parameter. In addition, sampling from the normal distribution can lead to unrealistic
(negative) parameter values (Figure 5 A). The credible intervals based on NAP underestimated
the patient’s risk to reach grade 4 neutropenia (Figure 5 B) as can also be seen in the posterior
probability of the nadir concentration (Figure 5 C). Considering a Student’s t distribution instead
of the normal approximation, as in [13], did not lead to an adequate improvement (Figure S 3).
Consequently, the NAP approach can result in over-optimistic, over-pessimistic and unrealistic
predictions. In contrast, the full Bayesian methods (SIR, MCMC and PF) adequately represent the
tails and respect the positivity constraint of parameter values. The resulting credible intervals are
comparable to the reference credible intervals. For illustration, Figure 6 A shows the approximation
error for the predicted probability of neutropenia grades, measured in the Hellinger distance (see
Eq. 13). Overall, SIR and PF showed the best approximation, while NAP resulted in the largest
errors.
Sequential DA processes patient data most efficiently
The need for real-time inference algorithms is increasing with the possibilities to more frequently
collect patient-specific data (online collection) during treatment. Sequential DA methods provide
an efficient framework for real-time data processing. At any time, all information (incl. associated
uncertainty) is present in a collection of particles that can be interpreted as representing the current
state and associated uncertainty of a patient via a virtual population. With a new datum, this
information is updated. Approaches that rely on batch data analysis, i.e. MAP, SIR, MCMC, need
to redo the inference from scratch. This has impact on the computational effort as the number of
data points increases. Figure 6 B shows a comparison of the computational cost to assimilate an
additional data point. All approaches show some kind of increase in effort every 21 days—due to
the IOV on some parameters. Clearly, PF shows lowest and almost constant costs, while for batch
mode approaches computational costs increase over time due to an increasing number of parameters
(one additional parameter for every cycle due to the IOV, see paragraph about the multiple cycle
study with paclitaxel) and an increasing integration time span to determine the likelihood. This
could become computationally expensive in view of long term treatments and higher time resolution
of data points provided by new digital health care devices. Figure 6 C summarises the features
of the different inference approaches. Note that all sampling-based approaches can be accelerated
by parallel computing. In summary, it was found that sequential DA processes patient monitoring
most efficiently and facilitated the handling of IOV because only the IOV parameter of the current
occasion needs to be considered.
Discussion
In the context of chemotherapy-induced neutropenia, we illustrated the severe drawbacks of MAP-
based approaches for forecasting and thereon based decision making. A prediction based on the
MAP estimate does neither correspond to the most probable outcome, nor does it allow to quantify
relevant risks as the uncertainties are not quantified. Both are highly undesirable characteristics
and make MAP-based inference difficult to interpret in a TDM setting. A normal approximation
of the posterior at the MAP estimate is no alternative, as it retains the same point estimate and
11
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Figure 5: Comparison of uncertainty quantification at the level of parameters, observ-
ables and quantities of interest. Exemplary comparison of the different methods for one patient
after having observed four data points up to day 5. (A) The posterior is shown for parameters
‘Slope’ and ‘Circ0’ showing the kernel density estimates of the sampling distribution univariately
and as scatter plots for the bivariate sampling distributions with contour plots for the full Bayesian
approach (reference) and the normal approximation located at the MAP estimate. (B) On the level
of the observable (neutrophil concentration) the point estimates (median or MAP) are displayed
along with the 90% credible intervals (CrI). For illustration purposes the prediction intervals are
not shown here. (C) The forecasted a-posteriori probability of the nadir concentration is shown
for the different approximations (histograms) in comparison with the reference (kernel density
estimate, black solid line).
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Figure 6: Comparison of methods regarding important aspects for model-informed
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proved to be unsuitable in case of skewed parameter distributions. We demonstrated that full
Bayesian approaches, like SIR, MCMC or PF provide accurate approximations to the posterior
distribution, enabling comprehensive uncertainty quantification of the quantities of interest (e.g.,
nadir concentration). Amongst the three considered approaches, PF is a sequential approach which
is beneficial in a more continuous monitoring context.
Uncertainty quantification in TDM is scarce. In [28] the SIR algorithm was previously used in
the TDM setting to construct credible intervals using a Student’s t distribution located at the
MAP estimate as importance function. A sequential approach in the context of MAP estimation
is discussed in [29] with a moving estimation horizon (window of data points that are considered).
A sequential DA approach has been investigated previously for glucose forecasting [30, 31], yet
not in combination with a NLME Modelling framework and without decision support statistics. A
systematic comparison of approaches, as presented herein is lacking.
In this study, particle filtering is applied in TDM within a NLME Modelling framework to represent
the current patient status via an uncertainty ensemble. A challenge in the application of PF is the
potential for weight degeneracy, i.e., a gradual separation into a few large and many very small
weights. A rejuvenation approach (as applied in this study) resolves this problem, but requires to
specify an additional parameter (magnitude of the rejuvenation). A too large value might result
in an artificially increased uncertainty, while a too small value might hinder exploration of the
parameter space. In the present application context, however, IOV counteracts in addition to the
rejuvenation step weight degeneracy.
Sequential data processing is not only computationally efficient and convenient for IOV handling,
but has the additional advantage that already assimilated experimental data need not be stored to
assimilate future data points. Sampling approaches allow a simple extension for hierarchical models
to include the uncertainties in the population parameters for an even more holistic uncertainty
quantification. This would enable a continuous learning process between clinical trials from drug
development (e.g. Phase III) and continue during the acquisition of real-world data after market
authorisation, in quantifying the diverse population of patients that have taken a given drug. For a
future patient, this ‘historic’ diversity would transform into well-quantified uncertainty in a TDM
setting. The absence of need to store ‘historic’ experimental data can also be helpful for the
exchange of information between clinics, health insurances and pharmaceutical companies. The
current knowledge, present in form of a sample of particles, can easily be exchanged without the
need to exchange the experimental data. The ‘historic’ data are implicitly present in the particles.
In view of new treatments and new mobile health care devices (e.g. wearables) gathering data
from various sources, clinicians have to deal with new challenges and an increasing complexity
of treatment decision-making which demands for comprehensive approaches that integrate data
efficiently and provide informative and reliable decision-support. We illustrated that comprehensive
uncertainty quantification can result in a more informative, reliable and differentiated decision-
support, which is not only limited to individualised chemotherapy but has the potential to improve
patient care in various therapeutic areas in which TDM is indicated, such as oncology, infectious
diseases, inflammatroy diseases, psychiatry, and transplantation patients.
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1 Introduction
This document should help to reproduce the simulation studies (along with the supplementary
MATLAB code), provide some more explanations and details and should be self-contained as
many parameters and models were taken from different publications.
2 Lognormal distribution
Since pharmacological parameters are typically positive, e.g., volume of distribution, baseline con-
centrations or rate constants, often a lognormal distribution is appropriate for modelling the inter-
individual variability between patients, i.e., θi = θ
TV · eηi with ηi ∼ N (0,Ω) for some individual
i. The lognormal distribution results from a transformation of a normal random variable. If
Y ∼ N (µ,Σ), then X = eY is lognormally distributed, i.e X ∼ LN (µ,Σ). The probability density
of the multivariate lognormal distribution is given by
p(x|µ,Σ) = 1
(2pi)d/2|Σ|1/2 ·
1∏
k xk
· e− 12 (logx−µ)TΣ−1(logx−µ) , (S 1)
where µ ∈ Rd and Σ ∈ Rd×d are the parameters of the associated normal distribution and log
denotes the natural logarithm.Thus, the prior for the individual parameters is given by
pΘ(θ) = LN (θ|log(θTV),Ω)
=
1
(2pi)d/2|Ω|1/2 ·
1∏
k θk
· e− 12 (log(θ)−log(θTV))TΩ−1(log(θ)−log(θTV)) .
3 Maximum a-posteriori (MAP) estimation
In MAP estimation, one seeks the parameter values that maximise the posterior probability
θˆMAPn = arg max
θ
p(θ|y1:n) .
It is, however, more convenient and numerically more stable to minimise the negative log-posterior
instead
θˆMAPn = arg min
θ
− log p(θ|y1:n)
= arg min
θ
− log p(y1:n|θ)− log p(θ) .
Choosing an additive normal residual error model (Yj = hj + j with j ∼iid N (0, σ2)) and a
lognormal IIV model for the parameters (θk = θ
TV
k · eηk with ηk ∼iid N (0, w2k)) yields
θˆMAPn = arg min
θ
n
2
log(2pi) +
n
2
log σ2 +
1
2
n∑
j=1
(yj − hj(θ))2
σ2
+
d
2
log(2pi) +
1
2
d∑
k=1
logω2k +
d∑
k=1
log θk +
1
2
d∑
k=1
(log(θk)− log(θTVk ))2
ω2k
with data y1:n = (y1, . . . , yn)
T observed up to time point tn. MAP estimation was performed in
Matlab R2017b using the interior-point algorithm in fmincon. The Matlab toolbox AMICI [1] was
used for simulation of the system of ordinary differential equations (ODEs) and for computations
of sensitivities used in gradient calculations (described below).
Gradient descent algorithms can often be improved by providing the gradient and the hessian of
the objective function J(θ) = − log p(θ|y1:n). The gradient for this specific problem is given by
∂J(θ)
∂θl
=−
n∑
j=1
(yj − hj(θ))
σ2
· ∂hj(θ)
∂θl
+
1
θl
+
(log(θl)− log(θTVl ))
ω2l
· 1
θl
,
2
and the hessian for l 6= m
∂2J(θ)
∂θl∂θm
=−
( n∑
j=1
(yj − hj(θ))
σ2
· ∂
2hj(θ)
∂θl∂θm
− 1
σ2
∂hj(θ)
∂θl
∂hj(θ)
∂θm
)
and
∂2J(θ)
∂θ2l
=−
( n∑
j=1
(yj − hj(θ))
σ2
· ∂
2hj(θ)
∂θ2l
− 1
σ2
∂hj(θ)
∂θl
∂hj(θ)
∂θl
)
+
1
θ2l
·
[ 1
w2l
(
1− log(θl) + log(θTVl )
)
− 1
]
.
Note that ∂hi(θ)∂θl = s
h
l are the output sensitivities, which are given by
shl =
∂h(x, θ)
∂x
sxl +
∂h(x, θ)
∂θl
,
using the sensitivities of the states
∂sxl
∂t
=
∂f(x, θ)
∂x
sxl +
∂f(x, θ)
∂θl
, sxl (0) =
∂x0(θ)
∂θl
.
For the computation of the state sensitivities the extended system of ODEs needs to be solved
x˙ = f(x, θ), x(0) = x0(θ)
s˙xl =
∂f(x, θ)
∂x
sxl +
∂f(x, θ)
∂θl
, sxl (0) =
∂x0(θ)
∂θl
.
Alternatively, the gradient could be computed via adjoint sensitivity analysis which is more efficient
for models with large number of states and parameters.
Since the hessian matrix requires the computation of the second-order sensitivities ∂
2hi(θ)
∂θl∂θm
, which
is computationally expensive, often the (expected) Fisher information matrix FIM is used as ap-
proximation
Ilm(θ) = −
n∑
i=1
1
σ2
· ∂hi(θ)
∂θl
· ∂hi(θ)
∂θm
,
and
Ill(θ) = −
(
n∑
i=1
1
σ2
· ∂hi(θ)
∂θl
· ∂hi(θ)
∂θl
+
1
ω2l θ
2
l
·
(
log(θTVl )− log(θl) + 1
))
.
It was found that the MAP estimate does not correctly transform under a nonlinear mapping
to the most probable observation/quantity of interest. As pharmacometric PK/PD models are
often nonlinear, this is a major drawback for decision support in MIPD. Figure S 1 (A) shows
the posterior of the drug effect parameter ‘Slope’ on the x-axis and the a-posteriori probability of
the nadir concentration on the y-axis. The blue line shows the MAP estimate for the parameter
‘Slope’ and links to the MAP-predicted nadir concentration, which clearly does not correspond
to the mode of the a-posteriori probability distribution of the nadir concentration. In addition
it is shown how some randomly chosen samples transform to the nadir concentration. Note,
however that the nadir concentration does of course not only depend on the ‘Slope’ but also on
the other parameters. Figure S 1 (B) demonstrates the same observation for a different quantity
of interest, the time of recovery to grade 2, which shows a bimodal posterior distribution. Further
we considered as a statistical measure of accuracy the root mean squared error (RMSE) between
the model-predicted outcome Ti(Sn) given data y1:n for individual i and the reference outcome
T ref (for which the data was simulated)
RMSE(T )n =
√√√√ 1
N
N∑
i=1
(Ti(Sn)− T refi )2 .
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1Supplement Figure 1: Illustration of the unfavourable propoerties of MAP estimation
with regard to reliable decision support. A The MAP estimate (blue line) does not correctly
transform under a nonlinear mapping to the most probable nadir concentration (based on [2, Figure
5.2]). The posterior of the parameter ’Slope’ is depicted for an exemplary patient after four data
points y1:4 were observed on the x-axis and the corresponding a-posteriori probability of the nadir
concentration on the y-axis (same scenario as in Figure 3). B The mode is not preserved under
transformation. The same scenario was considered as for part A. C Root mean squared error
(RMSE) of selected statistics. Comparison of the accuracy of the computed statistics cnadir, tnadir
and trec00 based on MAP estimation and full Bayesian inference (SIR using S = 10
3 samples).
The RMSE was computed across the whole considered virtual population N = 100.
Figure S 1 (C) shows the prediction accuracy of the point-estimates of MAP-estimation and of
the Full Bayesian approach over time. As more data points are taken into account the RMSE
decreases for both estimators. In the beginning of the cycle the Full Bayesian approach shows
increased accuracy across all considered quantities of interest.
4 Normal Approximation (NAP)
To quantify the uncertainty associated to a MAP estimate one may consider a quadratic approxi-
mation to the log posterior at its mode (following [3]). A Taylor expansion about the MAP estimate
results in
log p(θ|y1:n) ≈ log p(θˆMAP|y1:n)︸ ︷︷ ︸
=const.
+(θ − θˆMAP)T
[d log p(θ|y1:n)
dθ
]
θ=θˆMAP︸ ︷︷ ︸
=0
+
1
2
(θ − θˆMAP)T
[d2 log p(θ|y1:n)
dθ2
]
θ=θˆMAP
(θ − θˆMAP) .
If we take the exponential on both sides and normalise, we get as normal approximation to the
posterior at the MAP estimate
p(θ|y1:n) ≈ N
(
θˆMAP,
[
− d
2 log p(θ|y1:n)
dθ2
]−1
θ=θˆMAP
)
.
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The inverse of the variance can be decomposed using Bayes’ formula
− d
2
dθ2
log p(θ|y1:n) = − d
2
dθ2
log p(y1:n|θ)− d
2
dθ2
log p(θ) , (S 2)
where we retrieve the total observed Fisher information matrix (FIM)
I likelihood(θ) = − d
2
dθ2
log p(y1:n|θ) .
If the definition for the observed FIM of the likelihood is transferred to prior and posterior, the
previous decomposition Eq. S 2 can be written as
Ipost(θ) = I likelihood(θ) + Iprior(θ) ,
which allows to rewrite the normal approximation of the posterior as
p(θ|y1:n) ≈ N (θˆMAP, [Ipost(θˆMAP)]−1) . (S 3)
Note, that we defined I(θ) := Ipost(θ) in the main article. Since the MAP estimator is asymp-
totically normally distributed in the limit of large sample sizes (n → ∞) (see [3, appendix B] for
a proof), this approximation can be very precise in the case of highly informative data sets.
4.1 Simulation-based approach
To propagate the uncertainties from the parameters to the model predictions, we used a simulation-
based approach. To this end, we sampled from the normal distribution Eq. S 3 and subsequently
propagated each sample.
Step-by-step description of the algorithm
1. Generate posterior samples θ(s) from N (θˆMAP, [Ipost(θˆMAP)]−1) .
2. Compute for each sample h(tj , θ
(s)) for time points of interest j = 1, . . . ,m
3. Compute quantiles (hα/2, h1−α/2) for each time point tj
Similarly, we can compute samples of the quantities of interest T (s) = T (θ(s)).
4.2 Delta Method
As an alternative to the simulation-based approach, we may use the delta method to determine the
limiting distribution of a differentiable function of the parameters g(θ) [4, section 5.5]. In our case
g(θ) = h(x(t), θ). Using the Delta method, the uncertainties are propagated from the parameters
to the observable via the output sensitivities Sh(θˆMAP) = ∇θht(θ)
∣∣
θˆMAP
[4, section 5.5]:
p(ht(θˆ
MAP)|y1:n) ≈ N
(
h(x(t), θˆMAP), Sh(θˆMAP)TΣMAPSh(θˆMAP)
)
with ΣMAP = [I(θˆMAP)]−1. The credible interval (CI) for the prediction is then given by
CIα = h(x(t), θˆMAP)± z1−α/2
√
σ2CI(t) ,
where z1−α/2 is the quantile of the standard normal distribution and σ2CI is computed using the
output sensitivities
σ2CI(t) ≈ Sh(t, θˆMAP)TΣMAPSh(t, θˆMAP) .
Alternatively, the quantiles of the Student’s t distribution could be used as a more conservative
choice, see [5]. For the determination of the prediction interval (PI), the residual variability is
additionally taken into account
σ2PI(t) ≈ Sh(t, θˆMAP)TΣMAPSh(t, θˆMAP) + σ2RUV .
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Supplement Figure 2: Propagating uncertainties using the delta method instead of the simulation
based approach.
Note that, in the main manuscript σ2RUV = σ
2. Consequently, the prediction interval is given by
PIα = h(t, θˆMAP)± z1−α/2
√
σ2PI(t) ,
Since the delta method involves differentiation of g, it is not straightforward to apply the method
to any desired quantity of interest, e.g. g(θ) = T (θ) = Cnadir(θ).
The Delta method leads to a similar underestimation of the uncertainty as the simulation-based
approach (NAP sim), see Figure S 2. In addition it is not straightforward to propagate the
uncertainty to quantities of interest (therefore not displayed).
One option to overcome the underestimation of the uncertainty is the use of quantiles of the
Student’s t distribution instead of normal quantiles [5]. We have used quantiles of the Student’s
t distribution with ν = 4 degrees of freedom (NAP δ t). The credible intervals show an increased
width, but now overestimate the uncertainties regarding subtherapeutic areas (grade 0), see Figure
S 3. This is also not acceptable as underdosing is in oncology highly undesireable.
5 Sampling Importance Resampling (SIR)
Our goal is to generate samples from the posterior distribution at time point tn having observed
patient-specific data y1:n. For this importance sampling is used in the SIR algorithm. Let p˜(θ|y)
be the unnormalised posterior
p˜(θ|y1:n) = p(y1:n|θ) · p(θ).
We use the prior p(θ) = p(θ|θTV(cov),Ω) as importance function. This gives for a proposal sample
θ˜
(s)
n the unnormalised weights
w˜(s)n =
p˜(θ˜
(s)
n |y1:n)
p(θ˜
(s)
n )
= p(y1:n|θ˜(s)n ) ,
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Supplement Figure 3: Propagating uncertainties with the delta method using Student t quantiles.
which need to be normalised for an approximation of the normalised posterior distribution
w(s)n =
p(y1:n|θ˜(s)n )∑
s′ p(y1:n|θ˜(s
′)
n )
.
Step-by-step description of the algorithm
1. Sample proposals θ
(s)
n from prior p(θ|θTV,Ω)
2. Compute unnormalised importance weights w˜
(s)
n
3. Compute normalised importance weights w
(s)
n
4. Resample according to normalised importance weights w
(s)
n
Generally this algorithm needs a large number of samples, especially if there is a large disagreement
between prior and posterior. This is computationally very expensive, but can be run in parallel
up to the normalisation of the weights. The SIR algorithm is also used in the population analysis
context to improve the estimation of the parameter uncertainty distributions [6]. Thus, the SIR
approach might be an option to also take into account uncertainty in the population parameters
(hyper parameters).
Reference posterior
Since the true posterior distribution is analytically intractable, we employ as reference solution the
SIR algorithm with a large number of samples (S = 106), as the algorithm is exact for S → ∞.
To validate this reference we have compared it in addition to the posterior derived by the MCMC
algorithm using also S = 106 samples with a burn-in of 100 samples, see Figure S 7.
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Supplement Figure 4: Acceptance rate of the Metropolis Hastings algorithm with fixed proposal
variance (MHΩ) and with adapted proposal (MH adapted). The green lines mark the area of a
good acceptance rate balancing the trade-off between exploring the space and efficiently moving
the chain.
6 Markov chain Monte Carlo (MCMC)
We used in the presented study an adaptive version of the well-known Metropolis-Hastings algo-
rithm. In the TDM setting it was previously suggested to use the prior as fixed proposal (inde-
pendence sampler) [7] . We have, however, found that as the number of data points increases the
rejection rate increases (since the posterior is becoming narrower), leading to inefficient sampling
of the posterior. However, positioning the proposal (LN (·|Ω)) at the just accepted proposal also
showed high rejection rates. To counteract low acceptance rates, the proposal was therefore not
only moved to the just accepted proposal but was also adapted to the previous posterior sampling
distribution, e.g. θ0 = E[pˆ(log(θ)|y1:n−1]) and LN (·|θs−1,Cov[pˆ(log(θ)|y1:n−1]), see Figure S 4.
Since we employed the Metropolis-Hastings algorithm with a lognormal, thus asymmetric distri-
bution as a proposal, we have to use a correction term in the acceptance probability to account for
the asymmetry of the proposal distribution. Using Eq. S 1, we get the following acceptance ratio
in the case of a lognormal proposal distribution
α =
p(θ∗|y1:n)
p(θs−1|y1:n) ·
LN (θs−1|θ∗,Ω)
LN (θ∗|θs−1,Ω) =
p(θ∗|y1:n)
p(θj−1|y1:n) ·
∏
(θ∗)k∏
(θj−1)k
. (S 4)
The Markov chain was started at the typical value θTV(cov). Generally, a certain number of
samples in the beginning is discarded, a so called burn-in or warm-up. We chose a burn-in of 100
samples in our analysis.
The steps of the Metropolis-Hastings algorithm at time point tn are
1. Start chain at θ0 = θ
TV
For s = 1, . . . , S
2. Generate proposal θ∗ from the proposal distribution LN (θs−1,Ω)
3. Accept θ∗ with probability α defined in Eq. S 4.
One drawback of MCMC approaches is that standard MCMC methods cannot be used efficiently
in sequential inference context, as for every updated posterior distribution p(θ|y1:k) a new Markov
chain has to be generated [8].
7 Particle filter (PF)
The particle filter belongs to the class of sequential data assimilation methods. In sequential DA
methods, the posterior is iteratively updated via Bayes’ formula by combining computer-generated
Bayesian forecasts with data in real time. The most well-known sequential data assimilation
method is the Kalman filter [9, 10], which relies on the assumptions of linear model dynamics
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and Gaussian uncertainty, which reduced the problem to only track the mean and variance of
the posterior density over time. However, many problems in application do not satisfy these
assumptions. Therefore, particle filters (PF) [11] were developed that allow for non-Gaussian error
models and non-linear structural models, which fits the general pharmacometric setting. In this
section some more algorithmic details of the particle filter are described.
7.1 State augmentation
Filter algorithms were mainly developed for state estimation with fixed parameters. However, the
parameters can be added to an augmented state space z = (x, θ),
∂x
∂t
(t) = f(x(t); θ, u)
∂θ
∂t
(t) = 0 .
Since we are considering static parameters (within one cycle), the rate of change of parameters is
zero. The filter algorithm was then applied to the augmented state z(t) = (x(t), θ(t)).
7.2 Resampling strategies
There exist many different strategies on how to resample efficiently and effectively. The most
widely used are multinomial, residual and systematic resampling, see e.g. [12]. For this article,
we applied residual resampling. Resampling can be performed at every step (bootstrap filter) or,
more efficiently, only if the effective sample size is smaller than a threshold, e.g. Seff < S/2.
7.3 Rejuvenation
Resampling addresses the problem of weight degeneracy in particle filters, however, it introduces the
problem of sample impoverishment. Drawing with replacement among the particles results in many
identical particles. Since the structural model is deterministic with constant parameters, resampled
particles will remain identical over time. Particle rejuvenation can be applied to counteract this
sample impoverishment [13]. After each resampling new parameter particles are sampled from a
normal distribution centered around the previous parameter values with a small relative variance.
Since this only introduces small perturbations in the parameter space, we assumed that x(θ) ≈ x(θ˜)
for a rejuvenation of θ resulting in θ˜.
7.4 Smoothing
For smoothing over the past prediction the previously predicted paths are resampled along with
the states and parameters according to the current particle weights.
7.5 Alternative sequential DA algorithms
There exist many extensions, modifications and add-on techniques for particle filters. Depending
on how the analysis ensemble is generated from the forecast ensemble, different filter algorithms
are distinguished, see e.g. [14, 15]. Among these the class of ensemble transform filters [15] is
very promising as it replaces the stochastic resampling and rejuvenation step of the basic particle
filter by a deterministic transformation which allows to ensure certain properties, e.g. 2nd order
accuracy [14]. However, in the augmented state space the connection between the parameters
and states is lost as larger steps in the parameter steps are undertaken which means that the
assumption x(θ) ≈ x(θ˜) is no longer valid.
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0. Initialisation of particles {x(s)0 , θ(s)0 , w(s)0 }Ss=1
for all s = 1, . . . , S
sample θ(s)0 from p(θ; θˆTV (cov),Ω), xs0 from p(x0|θ) and set w(s)0 = 1/S
For j = 1, . . . , n
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1
Supplement Figure 5: Step-by-step description of the particle filter. The different steps
of the particle filter are depicted in the context of forecasting the time-course of neutropenia.
For illustration purposes the number of virtual individuals is reduced to S = 10. The different
shades represent the importance weights, the darker the colour the higher the importance weight.
From the initial virtual subpopulation only five are resampled (resulting in duplicate samples).
Rejuvenation introduces new virtual individuals who are similar to the five resampled ones.
8 Simulation study: Single cycle Docetaxel
In the simulation study we use as prior knowledge a population analysis of a clinical study by
Kloft et al. [16]. In this section more details about the employed models and parameter estimates
is provided. We aimed to be comparable to the setting in [17]. A virtual population (N = 100)
was generated based on the patient characteristics provided in [16]. The covariates AGE and AAG
were sampled from a normal distribution with mean given by the median and an estimated variance
from the given observed range. The parameter estimates used for the pharmacokinetic (PK) and
pharmacodynamic (PD) model are given in Table S 2. For the MAP estimation we needed to
provide parameter bounds to the optimiser. The lower bounds were taken from the code provided
by Netterberg [18] and the upper bounds were tested, so that the optimiser did not reach the
bound.
As PK model for Docetaxel a three compartment model with first-order elimination was employed
[21]. AAG (α1-acid glycoprotein), AGE, BSA (body surface area) and ALB (albumin) were found
as covariates on clearance. Patient specific parameter values were determined based on covariates.
The individual clearance is computed via
CLi = BSAi ·(CLTV+θCL-AAG ·AAGi+θCL-AGE ·AGEi+θCL-ALB ·ALBTV)·(1−θCL-HEP12 ·HEP12) ,
where we used ALBTV = 41 g/L and set HEP12=0 (i.e. no elevated hepatic enzymes). The
parameter estimates were taken from [21], see Supplement Table 1 and the system of ODEs for
the PK model is given by
dCent
dt
= u(t)− k10Cent + k21Per1− k12Cent + k31Per2− k13Cent , Cent(0) = 0
dPer1
dt
= k12Cent− k21Per1 , Per1(0) = 0
dPer2
dt
= k13Cent− k31Per2 , Per2(0) = 0 .
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Supplement Figure 6: Structural models for neutropenia. The gold-standard model for neu-
tropenia, developed by Friberg et al. [19] (black). Extended bone marrow exhaustion model, which
describes cumulative neutropenia over multiple cycles, developed by Henrich et al. [20] (black and
blue). The state variables and parameters of the models are described in the text.
Structural submodel
V 8.31 [L]
CLTV 22.1 [L/h]
k10 CL/V [1/h]
k12 1.07 [1/h]
k21 1.74 [1/h]
k13 1.28 [1/h]
k31 0.0787 [1/h]
Covariate submodel
θCL-AAG -3.55
θCL-AGE -0.095
θCL-ALB 0.225
Supplement Table 1: Pharmacokinetic parameter estimates for Docetaxel [21].
The semi-mechanistic model by Friberg et al. [19] describes chemotherapy-induced neutropenia and
consists of five compartments. The proliferating compartment (Prol) represents rapidly dividing
progenitor cells in the bone marrow, which replicate with rate kprol. Three transit compartments
(Transit 1-3) approximate the maturation chain of progenitor cells in the bone marrow to differen-
tiated neutrophils in the systemic circulation, with transition rate ktr. Circulating neutrophils in
blood (Circ) are the part of the system that can be observed. Thus, the state vector for the model
is given by
x(t) =
(
Prol(t),Transit1(t),Transit2(t),Transit3(t),Circ(t)
)T
,
with observable
h(t) = Circ(t) ,
and initial conditions
Prol(t0) = Transit 1(t0) = Transit 2(t0) = Transit 3(t0) = Circ(t0) = Circ0 .
The cytotoxic effect of anticancer drugs is implemented linearly on the proliferation rate of sus-
ceptible progenitor cells, so the effect is proportional to the drug concentration
Edrug(t) = Slope · Cdrug(t) ,
which is the input to the system
u(t) = Cdrug(t) ,
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Structural submodel
Circ0 5.22 [10
9cells/L]
MTT 84.2 [h]
Slope 15.6 [L/µmol]
γ 0.145 []
Covariate submodel
θCirc0-AAG≤1.34 0.175
θCirc0-AAG>1.34 0.495
θCirc0-SEX -0.121
θCirc0-PERF 0.131
θCirc0-PC -0.147
θSlope-AAG -0.351
Statistical submodel
σ2 0.180
ω2Circ0 0.0606
ω2MTT 0.0194
ω2Slope 0.122
ω2γ 0.0223
Supplement Table 2: Parameter estimates for the Friberg-model and Docetaxel taken from [16]
parameter lower bound upper bound
Circ0 [10
9cells/L] 2 30
MTT [h] 10 250
Slope [L/µmol] 0.01 60
Supplement Table 3: Bounds for MAP estimation. Lower bounds were taken from [18]
where the time-evolution is given by the corresponding PK model for Docetaxel. The effect of the
drug on the proliferation rate of the Prol compartement is described by a feedback, which leads to
an increase in production of white blood cells if the number of circulating neutrophils is decreasing,
and vice versa
Feedback(t) =
(
Circ0
Circ(t)
)γ
.
System parameters include the baseline neutrophil concentration (Circ0) before the start of treat-
ment, the mean transition time (MTT), which represents the average time for a progenitor cell
in the bone marrow to mature to a circulating neutrophil, and the slope parameter (Slope) of
the linear inhibitory model for the drug effect. Furthermore, γ is the exponent parameter for the
feedback model. Thus, the parameter vector for the model is given by
θ = (Circ0,MTT,Slope, γ)
T .
As in [17] we assume γ to be fixed. The system of ordinary differential equations (ODEs) reads
dProl
dt
= kprolProl · (1− Edrug) ·
(
Circ0
Circ
)γ
− ktrProl , Prol(0) = Circ0
dTransit1
dt
= ktrProl− ktrTransit1 , Transit1(0) = Circ0
dTransit2
dt
= ktrTransit1− ktrTransit2 , Transit2(0) = Circ0
dTransit3
dt
= ktrTransit2− ktrTransit3 , Transit3(0) = Circ0
dCirc
dt
= ktrTransit3− kcircCirc , Circ(0) = Circ0 .
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Supplement Figure 7: Comparison of reference posterior. The reference posterior was derived by
the SIR algorithm and with the MCMC algorithm using S = 106 samples.
9 Simulation study: Multiple cycles Paclitaxel
The multiple cycle simulation study is based on a population analysis [20] of the CEPAC-TDM
study data. For the data simulation it was assumed that every third day the neutrophil counts
were assessed for a patient undergoing chemotherapy. The data was simulated based on a model
prediction including interoccasion variability. Paclitaxel pharmacokinetics were described by a
three compartment model with nonlinear distribution to the first peripheral compartment and
nonlinear elimination [22]. The system of ODEs reads
dCent
dt
= u(t)− VMEL · C1
KMEL + C1
+ k21Per1− VMTR · C1
KMTR + C1
+ k31Per2− k13Cent , Cent(0) = 0
dPer1
dt
=
VMTR · C1
KMTR + C1
− k21Per1 , Per1(0) = 0
dPer2
dt
= k13Cent− k31Per2 , Per2(0) = 0
where C1(t) = Cent(t)/V1. We used the parameter values by [20], see Table S 4. The following
covariate model for VMEL was given as
VMEL,TV,i = VMEL,pop·
( BSAi
1.8m2
)θVMEL-BSA ·(θVMEL-SEX)SEXi ·( AGEi56years)θVMEL-AGE ·( BILIi7µmol/L)θVMEL-BILI
relating patient characteristics, BSA (body surface area), SEX, AGE and BILI (total bilirubin
concentration) to the maximum elimination capacity (VMEL). In addition to inter-individual
variability and residual variability, interoccasion variability was included on the two parameters
V1 and VMEL, where each start of a new cycle is defined as an occasion,
θi,o = θTV,i · eηi+κi,o , κi,o iid∼ N (0,Π2) .
Neutropenia has been observed to worsen over several treatment cycles, i.e. the lowest neutrophil
concentration (nadir concentration) and the maximum neutrophil concentration decreases over
multiple cycles. Bone marrow exhaustion could be one explanation of this cumulative behaviour,
which means that the long-term recovery of the bone marrow is also affected. The standard model
for neutropenia [19] does not take such a long-term effect into account. Henrich et al. [20] therefore
expanded the model by dividing the proliferating compartment into another stem cell compartment,
describing pluripotent stem cells with reduced proliferation rate. This model extension made it
possible to capture the cumulative long-term effect.
The proliferation rate constants for the proliferating compartement Prol and for the stem cell
compartement Stem are given by
kprol = ftr · ktr
kstem = (1− ftr) · ktr ,
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Structural submodel
V1 10.8 [L]
V3 301 [L]
KMEL 0.667 [µM]
VMEL,pop 35.9 [µmol/h]
KMTR 1.44 [µM]
VMTR 175 [µmol/h]
k21 1.12 [1/h]
Q 16.8 [1/h]
Covariate submodel
θVMEL-BSA 1.14
θVMEL-SEX 1.07
θVMEL-AGE -0.447
θVMEL-BILI -0.0942
Statistical submodel IIV
ω2V3 0.1639
ω2VMEL 0.0253
ω2KMTR 0.3885
ω2VMTR 0.077
ω2k21 0.008
ω2Q 0.1660
Statistical submodel IOV
pi2V1 0.1391
pi2VMEL 0.0231
Statistical submodel RV
σ2 0.0317
Supplement Table 4: Pharmacokinetic parameter estimates for the anticancer drug Paclitaxel [20].
respectively, where ftr is the fraction of input in the Prol compartment via proliferation within the
compartment. As the drug effect is proportional to the proliferation rate constant, the stem cells
are less affected by the treatment than the progenitor cells.
dStem
dt
= kstemStem · (1− Edrug) ·
(Circ0
Circ
)γ
− ktrStemStem , Stem0) = Circ0
dProl
dt
= kprolProl · (1− Edrug) ·
(Circ0
Circ
)γ
+ ktrStemStem− ktrProl , Prol(0) = Circ0
dTransit1
dt
= ktrProl− ktrTransit1 , Transit1(0) = Circ0
dTransit2
dt
= ktrTransit1− ktrTransit2 , Transit2(0) = Circ0
dTransit3
dt
= ktrTransit2− ktrTransit3 , Transit3(0) = Circ0
dCirc
dt
= ktrTransit3− kcircCirc , Circ(0) = Circ0
The baseline parameter Circ0 was inferred from the baseline data point ( baseline method 2 [23])
Circ0,i = yCirc0 · eθRV·ηCirc0,i , ηCirc0,i ∼ N (0, 1) .
In the bone marrow exhaustion model we have in addition to inter-individual variability (IIV)
inter-occasion variability (IOV). The parameter vector, thus, contains parameter values, which are
constant across occasions (cycles) θIIV and parameters that are specific for each cycle c, θIOVc .
θc = e
log(θTV)+η︸ ︷︷ ︸
=θIIV
· eκc︸︷︷︸
=θIOVc
. (S 5)
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Structural submodel
Circ0 baseline method [23] [10
9cells/L]
MTT 145 [h]
Slope 13.1 [L/µmol]
γ 0.257 []
ftr 0.787 []
Statistical submodel
σ2 0.2652
ω2Slope 0.2007
Supplement Table 5: Parameter estimates for the bone marrow exhaustion model and the anti-
cancer drug Paclitaxel .
The θIIV parameters need to be learned across all cycles and the cycle specific parameters θIOVc
based on the data observed in cycle c, y1:nc = (y1, . . . , ync)
T . The size of the parameter vector
that needs to be estimated will, therefore, grow with every occasion if the whole data is processed
in a batch. Assuming independence between the inter-individual and interoccasion variability, the
objective function for the MAP estimation is then given by
θˆMAPn = arg min
θIIV,θIOV
1
2
( C∑
c=1
nc∑
j=1
(
yj − hj(θ)
)2
σ2
+ 2
nIIVθ∑
k=1
log(θIIVk ) +
nIIVθ∑
k=1
(
log(θIIVk )− log(θTVk (cov))
)2
ω2k
+ 2
C∑
c=1
nIOVθ∑
k=1
log(θIOVk,c ) +
C∑
c=1
nIOVθ∑
k=1
(
log(θIOVk,c )− log(θTVk (cov))
)2
pi2k
)
for the IIV and IOV model θk,c = θ
TV
k · eηk+κk,c , with ηk ∼ N (0, w2k) and κk,c ∼ N (0, pi2k), for an
additive normal residual error model yj = hj + j , with j ∼ N (0, σ2) and for data observed up
to time point tn, i.e. n =
∑
c nc, with nc the number of observations made in cycle c.
The gradient with respect to the IIV parameters is then given by
∂J(θ)
∂θIIVl
=−
n∑
j=1
(yj − hj(θ))
σ2
· ∂hj(θ)
∂θIIVl
+
1
θIIVl
+
(log(θIIVl )− log(θTVl ))
ω2l
· 1
θIIVl
,
and with respect to the IOV parameters by
∂J(θ)
∂θIOVl,c
=−
n∑
j=1
(yj − hj(θ))
σ2
· ∂hj(θ)
∂θIOVl
+
1
θIOVl,c
+
(log(θIOVl )− log(θTVl ))
ω2l
· 1
θIOVl,c
,
Figure S 8 shows a comparison of the different methods in forecasting the third cycle. The scenario
corresponds to the situation presented in Figure 4 in the main manuscript. All full Bayesian meth-
ods provide almost overlapping credible intervals as well as point estimates (median). However,
the MAP-based forecasted trajectory deviates significantly from the point estimates (median) of
the full Bayesian methods.
In Figure S 9 the posterior approximations are compared to the reference on the level of the
parameters. In addition, we can observe the deviation of the posterior from the prior for parameters
’Slope’ and ’Circ0’. As we do not consider PK samples the knowledge gain about the PK parameters
is limited. All approximations show good agreement with the reference and the MAP estimate is
located at the mode of the posterior on the level of the parameters.
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Supplement Figure 8: Comparison of all methods for the standard dose. The third cycle is
forecasted in case the standard dose is given.
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eters for the scenario considered in Figure 8
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